SynDRep: a synergistic partner prediction tool based on knowledge graph for drug repurposing.

IF 2.8 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY
Bioinformatics advances Pub Date : 2025-06-05 eCollection Date: 2025-01-01 DOI:10.1093/bioadv/vbaf092
Karim S Shalaby, Sathvik Guru Rao, Bruce Schultz, Martin Hofmann-Apitius, Alpha Tom Kodamullil, Vinay Srinivas Bharadhwaj
{"title":"SynDRep: a synergistic partner prediction tool based on knowledge graph for drug repurposing.","authors":"Karim S Shalaby, Sathvik Guru Rao, Bruce Schultz, Martin Hofmann-Apitius, Alpha Tom Kodamullil, Vinay Srinivas Bharadhwaj","doi":"10.1093/bioadv/vbaf092","DOIUrl":null,"url":null,"abstract":"<p><strong>Motivation: </strong>Drug repurposing is gaining interest due to its high cost-effectiveness, low risks, and improved patient outcomes. However, most drug repurposing methods depend on drug-disease-target semantic connections of a single drug rather than insights from drug combination data. In this study, we propose SynDRep, a novel drug repurposing tool based on enriching knowledge graphs (KG) with drug combination effects. It predicts the synergistic drug partner with a commonly prescribed drug for the target disease, leveraging graph embedding and machine learning (ML) techniques. This partner drug is then repurposed as a single agent for this disease by exploring pathways between them in the KG.</p><p><strong>Results: </strong>HolE was the best-performing embedding model (with 84.58% of true predictions for all relations), and random forest emerged as the best ML model with an area under the receiver operating characteristic curve (ROC-AUC) value of 0.796. Some of our selected candidates, such as miconazole and albendazole for Alzheimer's disease, have been validated through literature, while others lack either a clear pathway or literature evidence for their use for the disease of interest. Therefore, complementing SynDRep with more specialized KGs, and additional training data, would enhance its efficacy and offer cost-effective and timely solutions for patients.</p><p><strong>Availability and implementation: </strong>SynDRep is available as an open-source Python package at https://github.com/SynDRep/SynDRep under the Apache 2.0 License.</p>","PeriodicalId":72368,"journal":{"name":"Bioinformatics advances","volume":"5 1","pages":"vbaf092"},"PeriodicalIF":2.8000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148216/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioinformatics advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/bioadv/vbaf092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Motivation: Drug repurposing is gaining interest due to its high cost-effectiveness, low risks, and improved patient outcomes. However, most drug repurposing methods depend on drug-disease-target semantic connections of a single drug rather than insights from drug combination data. In this study, we propose SynDRep, a novel drug repurposing tool based on enriching knowledge graphs (KG) with drug combination effects. It predicts the synergistic drug partner with a commonly prescribed drug for the target disease, leveraging graph embedding and machine learning (ML) techniques. This partner drug is then repurposed as a single agent for this disease by exploring pathways between them in the KG.

Results: HolE was the best-performing embedding model (with 84.58% of true predictions for all relations), and random forest emerged as the best ML model with an area under the receiver operating characteristic curve (ROC-AUC) value of 0.796. Some of our selected candidates, such as miconazole and albendazole for Alzheimer's disease, have been validated through literature, while others lack either a clear pathway or literature evidence for their use for the disease of interest. Therefore, complementing SynDRep with more specialized KGs, and additional training data, would enhance its efficacy and offer cost-effective and timely solutions for patients.

Availability and implementation: SynDRep is available as an open-source Python package at https://github.com/SynDRep/SynDRep under the Apache 2.0 License.

SynDRep:基于知识图谱的药物再利用协同伙伴预测工具。
动机:药物再利用因其高成本效益、低风险和改善患者预后而越来越受到关注。然而,大多数药物再利用方法依赖于单一药物的药物-疾病-靶标语义连接,而不是来自药物组合数据的见解。在这项研究中,我们提出了SynDRep,一个新的药物再利用工具,基于丰富的知识图谱(KG)与药物联合效应。它利用图嵌入和机器学习(ML)技术,预测与目标疾病的常用处方药的协同药物伙伴。然后通过在KG中探索它们之间的途径,将这种伴侣药物重新用作治疗这种疾病的单一药物。结果:HolE是表现最好的嵌入模型(对所有关系的预测准确率为84.58%),随机森林是表现最好的ML模型,其接收者工作特征曲线下面积(ROC-AUC)值为0.796。我们选择的一些候选药物,如治疗阿尔茨海默病的咪康唑和阿苯达唑,已经通过文献得到了验证,而其他药物则缺乏明确的途径或文献证据来证明它们用于治疗感兴趣的疾病。因此,为SynDRep补充更专业的kg和额外的培训数据,将提高其疗效,并为患者提供成本效益和及时的解决方案。可用性和实现:在Apache 2.0许可下,SynDRep作为开源Python包可在https://github.com/SynDRep/SynDRep上获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信